Monitor for any prospectus supplement announcing an actual offering — the going-concern qualification suggests a capital raise is likely needed, but the baby-shelf limit means any near-term offering will be small relative to the $250M shelf. Watch for a potential reverse stock split or other restructuring to regain Nasdaq compliance and expand future shelf capacity.
Price Chart
Executive Summary
Biomerica filed a $250M universal shelf registration statement (S-3) on September 24, 2026, registering common stock, preferred stock, debt securities, and warrants for potential future issuance. The filing includes a going-concern qualification from the auditor (Haskell & White LLP) in the most recent 10-K, indicating financial distress. The company's non-affiliate public float is only ~$11.9M, severely limiting the amount it can sell under the shelf's baby-shelf rules to ~$4M in any 12-month period, making the $250M figure largely aspirational.
Key Financial Metrics
Key Facts
- Filed S-3 shelf registration for up to $250,000,000 in securities (common, preferred, debt, warrants).
- Auditor's report on FY May 31, 2026 financials includes an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern.
- Non-affiliate public float as of September 23, 2026 was approximately $11,946,302, capping baby-shelf sales to ~$4M per 12-month period.
- Company sold approximately $716,105 of common stock under the prior shelf in the preceding 12 months.
- Common stock closed at $2.60 per share on September 23, 2026.
- No specific offering is being made at this time; the shelf provides flexibility for future capital raises.
Financial Impact
Shelf registration of up to $250M, but actual near-term dilution is constrained by the baby-shelf rule to roughly $4M given the ~$11.9M non-affiliate float.
Risk Factors
- Going-concern qualification signals high risk of needing dilutive financing or facing insolvency.
- Baby-shelf restrictions limit the amount the company can raise under this shelf, potentially forcing more expensive or restrictive financing alternatives.
- Low stock price ($2.60) and small float make any offering highly dilutive to existing shareholders.
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001493152-26-044169 |
| Exhibit: ex5-1.htm | 0001493152-26-044169 |
| Exhibit: ex107.htm | 0001493152-26-044169 |
| Exhibit: ex23-1.htm | 0001493152-26-044169 |
| Document: forms-3.htm | 0001493152-26-044169 |
| Document: 0001493152-26-044169-index-headers.html | 0001493152-26-044169 |
| Document: 0001493152-26-044169-index.html | 0001493152-26-044169 |
| Document: 0001493152-26-044169.txt | 0001493152-26-044169 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 9d ago | DEF 14A | $1.76 | awaiting T+20 | — | $1.72 (−2.27%) |
Oct 15, 2026 10d ago | 8-K | $1.85 | awaiting T+20 | — | $1.72 (−7.03%) |
Oct 8, 2026 18d ago | EFFECT | $1.89 | awaiting T+20 | — | $1.72 (−8.99%) |
Oct 8, 2026 18d ago | EFFECT | $1.89 | awaiting T+20 | — | $1.72 (−8.99%) |
Sep 25, 2026 4w ago | S-3 | $2.32 $1.68 | ▲ +27.59% | ▲ +26.11% | $1.72 (+25.86%) |
Sep 24, 2026 4w ago | S-3 | $2.32 $1.68 | ▲ +27.59% | ▲ +26.11% | $1.72 (+25.86%) |
Sep 1, 2026 7w ago | Press Release | $2.09 $2.26 | ▲ +8.13% | ▲ +7.82% | $1.72 (−17.70%) |
Aug 27, 2026 8w ago | Insider Cluster | $2.14 $2.39 | ▲ +11.68% | ▲ +12.16% | $1.72 (−19.63%) |
Aug 26, 2026 8w ago | 8-K | $2.10 $2.40 | ▼ −14.29% | ▼ −14.39% | $1.72 (+18.10%) |
Jun 4, 2026 20w ago | 8-K | $2.12 $1.73 | ▼ −18.40% | ▼ −20.26% | $1.72 (−18.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers